Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI ...
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and Nantes, France, 3 July 2024 – Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE …